Regulus Therapeutics CEO Joseph Hagan's 2021 pay falls 22% to $1.8M
Regulus Therapeutics reports 2021 executive compensation
By ExecPay News
Published: April 27, 2022
Regulus Therapeutics reported fiscal year 2021 executive compensation information on April 27, 2022.
In 2021, three executives at Regulus Therapeutics received on average a compensation package of $1.1M, a 13% decrease compared to previous year.
Average pay of disclosed executives at Regulus Therapeutics
Joseph P. Hagan, Chief Executive Officer, received $1.8M in total, which decreased by 22% compared to 2020. 52% of Hagan's compensation, or $954K, was in option awards. Hagan also received $289K in non-equity incentive plan, $568K in salary, as well as $11K in other compensation.
Christopher R. Aker, General Counsel, received a compensation package of $795K, which decreased by 2% compared to previous year. 43% of the compensation package, or $340K, was in salary.
Cris Calsada, Chief Financial Officer, earned $720K in 2021, a 2% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 27, 2022.